15 Oct 2018
The first biosimilars to be introduced in rheumatology came to the UK market in early 2015, however, their use in rheumatoid arthritis is set to soar with the introduction of 4 biosimilars when Adalimumab comes off patent on 16th October, 2018.
24 Sep 2018
Biosimilar medicines represent very good value for the NHS since they are often much less costly than the originator medicine. Therefore the NHS is asking clinical teams, in discussion with individual patients, to ensure they are using the best value biological medicines – whether that is the originator biological medicine or a new biosimilar medicine – so that the money saved can be reinvested in new medicines and treatments for patients.
20 Jun 2018
only 1 in 4 Brits knows what Rheumatoid Arthritis is. RA Awareness Week: 18-24 June. #ReframeRA